{"product_id":"lgd-4033-mk-677-mk-777","title":"LGD-4033 + MK-677 + MK-777","description":"\u003ch2\u003e\u003cspan\u003eLGD-4033 (Ligandrol) + MK-677 (Ibutamoren) + MK-777 (Acetamoren) | SARMs \u0026amp; Growth-Factor Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eAndrogen \u0026amp; Growth-Factor Signalling Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Androgen \u0026amp; Growth-Factor Signalling Research Set combines LGD-4033 (Ligandrol) 50×15mg, MK-677 (Ibutamoren) 50×15mg and MK-777 (Acetamoren) 50×15mg, creating a three-compound research format spanning selective androgen-receptor signalling and growth-hormone-secretagogue-associated research. The set contains one pot of each compound and is designed around comparative investigation of different molecular pathways rather than treating all three compounds as pharmacologically identical.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 is a genuine non-steroidal selective androgen receptor modulator. Its research history centres on androgen-receptor binding, tissue-selective signalling and downstream androgen-responsive pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 belongs to a fundamentally different pharmacological category. Also known as Ibutamoren, it is a non-peptide growth hormone secretagogue and established agonist of the ghrelin receptor, GHS-R1a. Research involving MK-677 has examined growth-hormone secretion, downstream IGF-1-associated signalling and broader endocrine and metabolic variables.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly known as Acetamoren, provides the third component. It is an emerging small-molecule research compound frequently positioned alongside MK-677 within the research market. However, its direct compound-specific evidence remains substantially less developed than the evidence available for Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Androgen \u0026amp; Growth-Factor Signalling Research Set therefore brings together one established androgen-receptor pathway with two compounds associated commercially with growth-hormone-secretagogue research, while maintaining appropriate distinction between their respective evidence levels.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe name reflects the scientific pathways represented within the set rather than guaranteeing a particular combined outcome. Each compound remains independently identified, enabling researchers to separate established pharmacology from newer hypotheses while examining multiple signalling systems within one structured research framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow LGD-4033, MK-677 and MK-777 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033, MK-677 and MK-777 create a multi-pathway research combination because they are associated with different areas of molecular and endocrine signalling. The principal distinction is between LGD-4033's established androgen-receptor activity and the growth-hormone-secretagogue-associated research surrounding MK-677 and MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 interacts with the androgen receptor, a ligand-regulated nuclear receptor involved in androgen-responsive transcription. As a non-steroidal selective androgen receptor modulator, Ligandrol has been investigated to determine how synthetic ligands can influence androgen-receptor activity and generate tissue-dependent experimental responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 operates through a different established pathway. Ibutamoren is an agonist of the growth hormone secretagogue receptor, commonly called GHS-R1a or the ghrelin receptor. Activation of this receptor has been investigated in relation to growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 is frequently associated with a similar commercial research category to MK-677, but the evidence surrounding Acetamoren is considerably thinner. It should therefore not automatically be assumed to possess identical receptor affinity, signalling characteristics or downstream activity to Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis makes the triple set useful for comparative pathway investigation. LGD-4033 provides a clearly characterised androgen-receptor component, MK-677 provides an established ghrelin-receptor and growth-hormone-secretagogue component, and MK-777 introduces an emerging compound requiring more cautious experimental interpretation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination itself does not establish synergy between the three compounds. Nor should evidence involving LGD-4033 or MK-677 automatically be transferred to MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value instead lies in examining different signalling pathways within a common research framework while maintaining compound-specific controls, appropriate analytical identification and clear separation between established findings and emerging research hypotheses.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eLGD-4033 (Ligandrol) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033, commonly known as Ligandrol and also associated with the developmental identifier VK5211, is a synthetic non-steroidal selective androgen receptor modulator. It represents the androgen-receptor-focused component of the BioPlex Androgen \u0026amp; Growth-Factor Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor belongs to the nuclear-receptor superfamily and functions as a ligand-regulated transcription factor. Interaction between an appropriate ligand and the receptor can alter receptor conformation, co-regulator recruitment and subsequent expression of androgen-responsive genes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 has been investigated as a high-affinity androgen-receptor ligand and forms part of the broader scientific effort to understand whether non-steroidal compounds can generate tissue-selective patterns of androgen-receptor activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts research history is substantially different from that of MK-677. Although both compounds are frequently sold within commercial SARMs categories, MK-677 does not primarily interact with the androgen receptor and should not be classified as a SARM.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction makes LGD-4033 particularly valuable within this three-compound set. It establishes a clearly defined androgen-receptor research pathway against which the different endocrine-signalling research surrounding MK-677 can be considered.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 introduces a further research question because its compound-specific evidence base remains much less developed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers should therefore avoid treating the three molecules as interchangeable or assuming that their placement within one set means they share the same mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Androgen \u0026amp; Growth-Factor Signalling Research Set, LGD-4033 provides the established SARM component. Its receptor pharmacology, tissue-selective research history and androgen-responsive endpoints can be examined independently while researchers separately investigate growth-hormone-secretagogue-associated pathways represented by the other compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis creates a broader comparative research framework than a set containing three molecules targeting only the androgen receptor.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eMK-677 (Ibutamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677, commonly known as Ibutamoren and also identified as MK-0677 or L-163,191, is a synthetic non-peptide growth hormone secretagogue. Unlike LGD-4033, MK-677 is not a selective androgen receptor modulator and does not derive its principal research activity from androgen-receptor signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts established molecular target is the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor. Ghrelin acts as an endogenous ligand within this receptor system, while MK-677 has been investigated as a synthetic agonist capable of activating ghrelin-receptor-associated signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving Ibutamoren has examined growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1. Experimental research has also explored appetite-associated signalling, metabolic variables, sleep-related measurements, body-composition endpoints and other physiological processes associated with the broader ghrelin and growth-hormone signalling systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis relatively developed research history makes MK-677 useful as the established growth-hormone-secretagogue component of this triple set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion alongside LGD-4033 creates a clear mechanistic contrast. Ligandrol provides selective androgen-receptor modulation, whereas Ibutamoren provides ghrelin-receptor agonism and growth-hormone-secretagogue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 then provides an emerging third comparison associated commercially with related research themes but supported by a much smaller direct evidence base.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Androgen \u0026amp; Growth-Factor Signalling Research Set, MK-677 should therefore be considered independently rather than being grouped pharmacologically with LGD-4033 simply because both compounds appear within the wider BioPlex capsule research range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts established receptor classification provides researchers with a defined molecular pathway that can be investigated alongside androgen-receptor signalling while retaining separate experimental controls and endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction supports more accurate comparative research and prevents commercial product categorisation from being mistaken for scientific classification.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-777 (Acetamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly referred to as Acetamoren, is an emerging synthetic small-molecule research compound that has increasingly appeared within research-compound catalogues alongside MK-677 Ibutamoren and compounds commercially grouped within SARMs ranges.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe available evidence surrounding MK-777 requires substantially greater caution than the evidence available for either LGD-4033 or MK-677.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 possesses an established research classification as a selective androgen receptor modulator, while MK-677 has a documented pharmacological relationship with the growth hormone secretagogue receptor GHS-R1a. MK-777 does not currently possess an equivalent publicly accessible body of compound-specific pharmacological research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAcetamoren is frequently positioned commercially within growth-hormone-secretagogue-associated research and compared with MK-677. However, commercial classification or naming similarity should not be treated as proof that MK-777 possesses identical receptor affinity, potency, pharmacokinetics or downstream signalling behaviour to Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis evidence distinction is particularly important within the Androgen \u0026amp; Growth-Factor Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 provides an emerging research component that can be considered alongside two better-characterised reference compounds. LGD-4033 establishes the androgen-receptor pathway, while MK-677 establishes the recognised ghrelin-receptor and growth-hormone-secretagogue pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers investigating MK-777 can therefore distinguish observations involving Acetamoren from the established pharmacology of the other compounds rather than transferring findings from MK-677 directly onto MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value of MK-777 within this combination consequently comes partly from the unanswered questions surrounding its classification and molecular activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eCareful compound identification, appropriate experimental controls and independent interpretation remain particularly important. This allows emerging MK-777 research to develop without overstating the current evidence or presenting proposed mechanisms as though they were already established pharmacological facts.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related androgen-receptor and growth-hormone-secretagogue research compounds from the BioPlex capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/lgd-4033-ligandrol-br-50x15mg\" title=\"LGD-4033 Ligandrol | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView LGD-4033 Ligandrol 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-677-ibutamoren-br-50x15mg\" title=\"MK-677 Ibutamoren | Growth Hormone Secretagogue Research | BioPlex UK\"\u003e\u003cspan\u003eView MK-677 Ibutamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-777-acetamoren-br-50x15mg\" title=\"MK-777 Acetamoren | Research Compound Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-777 Acetamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Related Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering LGD-4033, MK-677, MK-777, androgen-receptor activity and growth-hormone-secretagogue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-677-ibutamoren-research-overview\" title=\"MK-677 Ibutamoren Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-677 Ibutamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-777-acetamoren-research-overview-research-studies\" title=\"MK-777 Acetamoren Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-777 Acetamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-mk-777-vs-mk-677-compound-classification-research-pathways-and-key-differences\" title=\"MK-777 vs MK-677 | Research Pathways \u0026amp; Key Differences | BioPlex Peptides\"\u003e\u003cspan\u003eRead MK-777 vs MK-677: Research Pathways \u0026amp; Key Differences ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753852080512,"sku":null,"price":130.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MK-677_LGD-4033_MK-777.png?v=1787433697","url":"https:\/\/bioplexpeptides.co.uk\/es\/products\/lgd-4033-mk-677-mk-777","provider":"BioPlexPeptides.co.uk","version":"1.0","type":"link"}